Lifecore amends ABL facility with FILO tranche; still faces Nasdaq delisting risk

On May 10, 2024, Lifecore Biomedical, Inc. (the “ Company ”), Curation Foods, Inc. (“ Curation ”) and Lifecore Biomedical Operating Company, Inc. (together with the Company and Curation, the “ Borrowers ”), and BMO Bank N.A. (f/k/a BMO Harris Bank N.A.) (“ BMO ”) entered into that certain Seventh Amendment to Credit Agreement (the “ FILO Amendment ”), which amended that certain Credit Agreement, dated as of December 31, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date of the FILO Amendment, the “ ABL Credit Agreement ” and the ABL Credit Agreement, as amended by the FILO Amendment, the “ Amended ABL Credit Agreement ”), by and among, inter alios, the Borrowers and BMO.